Article

Medicare Proposes Covering Newly Approved Cologuard Test for CRC Detection

The final decision on the proposal will be made only after a 30-day comment period.

Medicare beneficiaries may get speedier coverage for a newly approved screening test for colorectal cancer under a pilot project in which two federal agencies reviewed the product at the same time instead of one after the other.

The Cologuard test, which detects the presence of DNA mutations that may be cancers in the stool, was approved by the Food and Drug Administration this week. The same day, the Centers for Medicare& Medicaid Services issued a proposal to cover the test once every three years in asymptomatic people over age 50 who are at average risk for the disease.

It’s the first time the agencies have undertaken a parallel review, and it could trim up to six months off the time it takes to offer Medicare coverage for a medical device, according to Nancy Stade, deputy director for policy at the FDA’s Center for Devices and Radiological Health in the FDA news release.

Although CMS has proposed covering the test, a final decision won’t be made until after a 30-day comment period.

Link to the original report: http://bit.ly/1AjPTak

Source: Kaiser Health News

Related Videos
Nini Wu, MD, Navista
Dr Emma Achola-Kothari
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Lalan Wilfong, MD
Katherine Baker, MD, MMHC
Nini Wu, MD, MBA
Casey Koch, PharmD, sitting for a video interview
Andrew Chapman, DO
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo